ArticleThe Australasian journal of dermatology2026
Merkel Cell Carcinoma in Queensland: Treatment, Incidence and Outcomes Over a 10-Year Period (2012-2021).
Article in The Australasian journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMerkel Cell Carcinoma (MCC) is a rare skin cancer with aggressive behaviour. We present results for incidence and outcomes of MCC in Queensland, a population having the highest rates of skin cancer worldwide.
methodsData for patients diagnosed with MCC between 2012 and 2021 were obtained from the population-based Queensland Oncology Repository. The age-standardised incidence rate trend was assessed using Joinpoint regression. Five-year MCC-specific survival was estimated using the Kaplan-Meier method and factors independently associated with survival were determined from a Fine-Grey multivariable model.
resultsA total of 1061 patients with MCC were included. Median age at diagnosis was 78 years, 68% were male and 27% were immunocompromised. Nearly all patients (94%) received treatment within 365 days of diagnosis, of whom 79% had surgery, 58% had radiotherapy and 15% had intravenous systemic therapy, either alone or in combination with other modalities. The average annual incidence rate was 1.89 per 100,000 population and remained stable over the study period (p
conclusionOur results indicate that the incidence of MCC in Queensland has stabilised following a long period of rapid increases. MCC-specific survival is improving, mostly for more advanced tumours, which is likely attributable to increasing use of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.